Actively Recruiting
Evaluating the Salvia PRIMUS System for Preventing Chronic Cluster Headaches in Adults Who Did Not Respond to Verapamil
Led by Salvia BioElectronics · Updated on 2026-07-16
10
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Salvia PRIMUS implantable neurostimulator system for preventing Chronic Cluster Headaches CCH in people who have not responded well to the drug verapamil. This limited open-label study takes place at two centers in the Netherlands and aims to understand patients experiences with this combined nerve stimulation treatment. The PRIMUS system is a small device implanted under the skin that stimulates both the Trigeminal nerve branches around the forehead and eye, and the Occipital nerves at the back of the head. It delivers mild electrical pulses using two stimulation waveforms a paresthesia-free burst waveform and a paresthesia-provoking tonic waveform. The treatment focuses on modulating headache neural networks to reduce pain and headache frequency by normalizing brain activity in certain areas. Participants will receive this combined nerve stimulation treatment and be monitored for safety over 12 weeks. Researchers will assess safety and gather information on how patients experience using the device. The study starts with screening and enrollment, then follows participants through treatment and observation. The trial is expected to be completed by December 2028.
CONDITIONS
Brief Title
Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache
Research Team
R
Rolf Fronczek, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here